Showing results (291-300 of 339) with videos related to
Sort By:
Pageof 34
Annals of the Rheumatic Diseases|August 16, 2022
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remissionGabriele Gamerith, Finn Mildner, Peter A Merkel, et al.Nature Communications|February 27, 2026
NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumorsDominik Humer, Victoria Klepsch, Dietmar Rieder, et al.Circulation Research|October 3, 2009
Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide-dependent mechanismWilfried Schgoer, Markus Theurl, Johannes Jeschke, et al.ESMO Open|November 24, 2020
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinomaAndreas Seeber, Kai Zimmer, Florian Kocher, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2014
Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study GroupThomas Schroeder, Elena Rachlis, Gesine Bug, et al.Blood|March 5, 2016
BRAF inhibition in hairy cell leukemia with low-dose vemurafenibSascha Dietrich, Andreas Pircher, Volker Endris, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2025
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLCTetsuya Mitsudomi, John V Heymach, Martin Reck, et al.Annals of Hematology|December 23, 2022
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study groupSteffen Koschmieder, Susanne Isfort, Dominik Wolf, et al.Transplantation and Cellular Therapy|July 2, 2026
Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple MyelomaIrene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, et al.Nature Communications|January 31, 2015
Methylation of ribosomal RNA by NSUN5 is a conserved mechanism modulating organismal lifespanMarkus Schosserer, Nadege Minois, Tina B Angerer, et al.Pageof 34